| Issue Date | Title | Author(s) |
| 2015 | Comparison of Major-Bleeding Risk and Health Care Costs Among Treatment-Naïve Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin | Amin, Alpesh; Keshishian, A; Xie, L; Başer, Onur ; Price, K; Vo, L; Singh, P; Bruno, A; Mardekian, J; Tan, W; Singhal, S; Patel, C; Odell, K; Trocio J. |
| 2015 | Comparison of Short Term Bleeding-Related Health Care Utilization and Costs Among Treatment-Naïve Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivoxaban or Warfarin | Keshishian, A; Xie, L; Başer, Onur ; Price, K; Vo, L; Singh, P; Bruno, A; Mardekian, J; Tan, W; Singha, S; Patel C; Odell, K; Trocio J. |
| 2015 | Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin | Alpesh, A; Keshishian, A; Xie, L; Başer, Onur ; Price, K; Vo, L; Singh, P; Bruno, A; Mardekian, J; Tan, W; Singhal, S; Patel, C; Odell, K; Trocio J. |
| 2016 | Real-World Comparison of Major Bleeding and Associated Costs Among Treatment-Naïve Nonvalvular Atrial Fibrillation Patients Initiating Apixaban or Warfarin | Amin, Alpesh; Keshishian, A; Xie L; Başer, Onur ; Price, K; Vo, L; Mardekian, J; Mendoza, M; Singhal, S; Patel, C; Odell, K; Trocio, J |
| 2016 | Real-World Comparison of Major Bleeding Risk Among Untreated Non-Valvular Atrial Fibrillation Patients and Those Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin | Amin, Alpesh; Keshishian, A; Xie, L; Başer, Onur ; Price, K; Lien Vo; Mardekian, J; Mendoza, M; Singhal, S; Patel, C; Odell, K; Trocio J. |
